 |
PDBsum entry 8huk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transcription
|
PDB id
|
|
|
|
8huk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Transcription
|
|
|
Title:
|
|
X-ray structure of human ppar alpha ligand binding domain- lanifibranor-src1 coactivator peptide co-crystals obtained by soaking
|
|
Structure:
|
|
Peroxisome proliferator-activated receptor alpha. Chain: a, c. Engineered: yes. 15-meric peptide from nuclear receptor coactivator 1. Chain: b. Engineered: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Organism_taxid: 9606
|
|
Resolution:
|
|
|
2.98Å
|
R-factor:
|
0.201
|
R-free:
|
0.254
|
|
|
Authors:
|
|
S.Kamata,R.Ishikawa,M.Akahane,A.Honda,T.Oyama,I.Ishii
|
|
Key ref:
|
|
S.Kamata
et al.
(2023).
Functional and structural insights into the human ppa / delta / gamma targeting preferences of anti-Nash investigational drugs, Lanifibranor, Seladelpar, And elafibranor.
Antioxidants,
12,
1523.
PubMed id:
|
|
|
Date:
|
|
|
24-Dec-22
|
Release date:
|
09-Aug-23
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
Q07869
(PPARA_HUMAN) -
Peroxisome proliferator-activated receptor alpha from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
468 a.a.
259 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
|
|
|
|
|
|
|
|
|
|
|
|
Enzyme class:
|
|
E.C.2.3.1.48
- histone acetyltransferase.
|
|
|
|
|
|
|
Reaction:
|
|
L-lysyl-[protein] + acetyl-CoA = N6-acetyl-L-lysyl-[protein] + CoA + H+
|
|
|
|
|
|
L-lysyl-[protein]
|
+
|
acetyl-CoA
|
=
|
N(6)-acetyl-L-lysyl-[protein]
|
+
|
CoA
|
+
|
H(+)
|
|
|
|
|
|
|
|
|
|
|
|
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
|
|
Links
